Ocuphire Pharma Investor Day Presentation Deck slide image

Ocuphire Pharma Investor Day Presentation Deck

P 85 VEGA-1: Mean Pupil Diameter Over Time Achieved Optimal Pupil Size in Nyxol+LDP (& Nyxol) Consistent with 3-line Near Vision Gain Mean Pupil Diameter (mm) 5 4 1 4.5 4.5 +4 4.5 4.4 Daily Evening Nyxol Dosing 12 hr minimum interval to Time 0 Baseline *** ***4.5 4.3 3.2 3.1 0 *** T 4.5 *** 3.2 HH 3.0 2.4 *** *** ** 1 Placebo (n=43) 4.4 3.2 2.5 2.1 VEGA-1 Phase 2 Trial Best Eye (PP Population) Mean Photopic Pupil Diameter *** *** ** 2 4.3 3.4 2.7 2.3 Time (Hours) *** -Nyxol+LDP (n=43) *** 4.4 3.3 *** 3.1 Nyxol+LDP arm statistically significant compared to all arms 3 2.5 -Nyxol (n=30) *** HH *** I *** 4 4.4 3.3 3.3 2.7 Placebo + LDP (n=31) Source: VEGA-1 TLR Table 14.2.12.1 Observed Values and Change from Baseline in Photopic Pupil Diameter by Time Point (PP Population) LO **p<0.01 ***p<0.0001 5 3.3 Both components maintained dynamic pupillary response *** 3.6 *** 2.9 4.6 6 Ocuphire PHARMA
View entire presentation